22nd Century Group Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for 22nd Century Group.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Tobacco earnings growth	18.2%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

Market Participants Recognise 22nd Century Group, Inc.'s (NASDAQ:XXII) Revenues Pushing Shares 1,233% Higher

Apr 02

Time To Worry? Analysts Just Downgraded Their 22nd Century Group, Inc. (NASDAQ:XXII) Outlook

Aug 20

With 22nd Century Group, Inc. (NASDAQ:XXII) It Looks Like You'll Get What You Pay For

Jun 14

Does 22nd Century Group (NASDAQ:XXII) Have A Healthy Balance Sheet?

Jan 13

22nd Century adds Creager as distribution partner for its VLN cigarettes in Colorado

Oct 03

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as 22nd Century Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:XXII - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	19	-51	-27	-25	N/A
3/31/2024	19	-63	-43	-40	N/A
12/31/2023	22	-65	-61	-55	N/A
9/30/2023	27	-101	-75	-69	N/A
6/30/2023	27	-41	-75	-69	N/A
3/31/2023	30	-38	-67	-61	N/A
12/31/2022	28	-37	-56	-52	N/A
9/30/2022	49	-47	-41	-37	N/A
6/30/2022	39	-44	-32	-30	N/A
3/31/2022	30	-36	-28	-27	N/A
12/31/2021	31	-33	-24	-23	N/A
9/30/2021	23	-25	-22	-21	N/A
6/30/2021	25	-20	-17	-16	N/A
3/31/2021	28	-21	-15	-15	N/A
12/31/2020	28	-20	-16	-16	N/A
9/30/2020	28	-20	-16	-16	N/A
6/30/2020	27	-26	-18	-17	N/A
3/31/2020	27	-29	-16	-15	N/A
12/31/2019	26	-27	-16	-15	N/A
9/30/2019	26	-29	-18	-17	N/A
6/30/2019	26	-13	-20	-18	N/A
3/31/2019	27	-11	-20	-19	N/A
12/31/2018	26	-8	-19	-18	N/A
9/30/2018	25	-3	-16	-15	N/A
6/30/2018	24	-12	-15	-13	N/A
3/31/2018	20	-9	N/A	-13	N/A
12/31/2017	17	-13	N/A	-12	N/A
9/30/2017	14	-12	N/A	-12	N/A
6/30/2017	13	-11	N/A	-11	N/A
3/31/2017	11	-11	N/A	-10	N/A
12/31/2016	12	-12	N/A	-10	N/A
9/30/2016	12	-12	N/A	-10	N/A
6/30/2016	11	-12	N/A	-10	N/A
3/31/2016	11	-10	N/A	-8	N/A
12/31/2015	9	-11	N/A	-7	N/A
9/30/2015	6	-14	N/A	-8	N/A
6/30/2015	3	-14	N/A	-8	N/A
3/31/2015	1	-14	N/A	-8	N/A
12/31/2014	1	-16	N/A	-7	N/A
9/30/2014	8	-18	N/A	2	N/A
6/30/2014	8	-30	N/A	3	N/A
3/31/2014	8	-29	N/A	4	N/A
12/31/2013	7	-26	N/A	4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if XXII's forecast earnings growth is above the savings rate (2.5%).

Earnings vs Market: Insufficient data to determine if XXII's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if XXII's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if XXII's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if XXII's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if XXII's Return on Equity is forecast to be high in 3 years time

22nd Century Group Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

No longer forecast to breakeven

Consensus EPS estimates fall by 67%

Consensus revenue estimates fall by 11%

Price target decreased by 27% to US$31.19

Consensus revenue estimates increase by 10%, EPS downgraded

22nd Century Group, Inc. Provides Revenue Guidance for the Full Year 2023

Recent updates

New major risk - Share price stability

22nd Century Group, Inc. announced that it expects to receive $1.6815 million in funding

Second quarter 2024 earnings released: US$0.36 loss per share (vs US$22.45 loss in 2Q 2023)

22nd Century Group, Inc. to Report Q2, 2024 Results on Aug 13, 2024

22nd Century Group, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

22Nd Century Group, Inc. Appoints Robert Manfredonia as Executive Vice President of Sales and Marketing, Effective from August 1, 2024

22nd Century Group, Inc. Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

22nd Century Group, Inc. to Report Q1, 2024 Results on May 15, 2024

22nd Century Group, Inc., Annual General Meeting, Jun 28, 2024

22nd Century Group, Inc. announced that it has received $4.2 million in funding

22nd Century Group, Inc. has filed a Follow-on Equity Offering in the amount of $4.237199 million.

22nd Century Group Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Nasdaq's Listing Rule 5550(b)(1)

Market Participants Recognise 22nd Century Group, Inc.'s (NASDAQ:XXII) Revenues Pushing Shares 1,233% Higher

New major risk - Share price stability

No longer forecast to breakeven

Full year 2023 earnings released: US$3.12 loss per share (vs US$4.65 loss in FY 2022)

22nd Century Group, Inc. to Report Q4, 2023 Results on Mar 28, 2024

22Nd Century Group, Inc. Announces Termination of Peter Ferola as the Chief Legal Officer and Corporate Secretary

High number of new directors

22Nd Century Group, Inc. Appoints Lawrence (Larry) Firestone as Chief Executive Officer

Specialty Acquisition Corporation entered into a equity purchase agreement to acquire Substantially all of GVB hemp/cannabis business from 22nd Century Group, Inc. (NasdaqCM:XXII) and ESI Holdings, LLC for $2.3 million.

Consensus EPS estimates fall by 67%

New major risk - Market cap size

22nd Century Group Receives Non-Compliance Letter from Nasdaq

22nd Century Group, Inc. Continues VLN Expansion, Now Retailing in More Than 5,100 Stores

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Shareholder dilution

22Nd Century Group, Inc. Adds 1,200 Drug Store Locations Selling VLN in Five States

Consensus revenue estimates fall by 11%

Time To Worry? Analysts Just Downgraded Their 22nd Century Group, Inc. (NASDAQ:XXII) Outlook

Price target decreased by 27% to US$31.19

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

22nd Century Group, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Pomerantz LLP Announces Pendency of Class Action and Proposed Settlement Involving Purchasers of 22nd Century Group, Inc. Common Stock

High number of new directors

22Nd Century Group, Inc. Announces Chief Executive Officer Changes

22nd Century Group Regains Compliance with Nasdaq Listing Standards

22Nd Century Group, Inc. Announces Its Vln(R) Reduced Nicotine Content C-Stores

New minor risk - Share price stability

22nd Century Announces 1-For-15 Reverse Stock Split to Regain Compliance with the Minimum Bid Price Requirement

New minor risk - Market cap size

22nd Century Group, Inc. Announces Production of VLN(R) Homogenized Tobacco Leaf Sheet

22nd Century Group, Inc. Announces VLN(R) Products Launch in Nevada to Help Smokers Smoke Less

With 22nd Century Group, Inc. (NASDAQ:XXII) It Looks Like You'll Get What You Pay For

22Nd Century Group, Inc. Launches Vln At #1 U.S. C-Store Chain in Texas, California and Florida

Consensus revenue estimates increase by 10%, EPS downgraded

22nd Century Group, Inc. Provides Revenue Guidance for the Full Year 2023

Price target decreased by 11% to US$4.00

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

22nd Century Group, Inc. to Report Q1, 2023 Results on May 09, 2023

Consensus EPS estimates fall by 16%

Full year 2022 earnings: EPS and revenues miss analyst expectations

22nd Century Group, Inc. (NasdaqCM:XXII) acquired Rx Pharmatech Ltd for $0.65 million.

Does 22nd Century Group (NASDAQ:XXII) Have A Healthy Balance Sheet?

Forecast to breakeven in 2025

Key Executive notifies of intention to sell stock

22Nd Century Group, Inc. Appoints John J. Miller as an Executive Officer and President of Tobacco

High number of new directors

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

High number of new directors

22nd Century Group, Inc. to Report Q3, 2022 Results on Nov 08, 2022

22nd Century adds Creager as distribution partner for its VLN cigarettes in Colorado

High number of new directors

22Nd Century Group Appoints Lucille S. Salhany to Its Board

22Nd Century Group, Inc. Announces Executive Changes

22nd Century Group to expand sales of VLN tobacco cigarettes